Crestor (rosuvastatin) is NOT effective at preventing heart attack or death says two cardiologists
Thursday, June 02, 2016 4:43 pm Email this article
“Our systematic review [of four (4) randomized controlled trials published since 2005/2006] ... unambiguously showed that rosuvastatin [Crestor] is not effective in secondary prevention, while the results are highly debatable in primary prevention,” notes a recent review paper by French cardiologist, Michel de Lorgeril, MD and Swiss cardiologist, Mikael Rabaeus, MD.
In other words, statins don’t work even in people who have had a heart attack!
Secondary prevention is when they give a drug—a statin in this case—to people who have had a heart attack or have cardiovascular disease and they are trying to prevent another heart attack or death.
Primary Prevention is when they give a drug—a statin in this case—to people who do not have cardiovascular disease or have not had a heart attack and are trying to prevent a heart attack or death in the first place.
They Looked At Statin Trials Published Since 2005/2006
They looked at studies published since 2005/2006 because “Around the years 2005/2006, new stricter Regulations were introduced in the conduct and publication of randomized controlled trials” they noted.
I No Longer Believe ANY Drug Company-Sponsored Studies
I no longer believe ANY study sponsored by the drug companies or ANY papers written by people paid by the drug companies as I noted in 2014.
The drug companies have been caught lying too many times.
de Lorgeril M, and Rabaeus M. Beyond Confusion and Controversy, Can We Evaluate the Real Efficacy and Safety of Cholesterol-Lowering with Statins? Journal of Controversies in Biomedical Research, 2015; 1(1): 67-92. http://jcbmr.com/index.php/jcbmr/article/view/11/26.
Author’s Contact Info
Michel de Lorgeril, MD
TIMC-IMAG CNRS UMR 5525
Laboratoire Cœur et Nutrition
Université Joseph Fourier
About Michel de Lorgeril, MD
Researchgate.net notes that:
“Michel de Lorgeril is a cardiologist and nutritionist at the French National Centre for Scientific Research and the School of Medicine at Grenoble University, France.
“In the 1990s he proposed a theory to explain the French paradox (low mortality rate from cardiac disease in France compared with UK and USA despite similar risk profiles), and his research group demonstrated that the plant omega-3 fatty acid (alpha-linolenic acid) is cardioprotective.
“Michel de Lorgeril was the principal investigator on the landmark Lyon Diet Heart Study, the first clinical trial to demonstrate the beneficial effects of the Mediterranean diet in the prevention of ischemic heart disease.”